NEVRO CORP. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2016-12-20: Form 8-K; Period of report 2016-12-19; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Details 1.01.
- 2016-12-09: Form 8-K; Period of report 2016-12-09; Description 8.01 Other Events; Details 8.01.
- 2016-11-29: Form 8-K; Period of report 2016-11-28; Description 8.01 Other Events; Details 8.01.
- 2016-11-22: Form 8-K; Period of report 2016-11-16; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2016-12-20 | 8-K | 2016-12-19 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 (a) Creation of a Direct Financial Obligation. | nvro-8k_20161219.htm |
| 2016-12-09 | 8-K | 2016-12-09 | 8.01 Other Events | 8.01 On December 9, 2016, Nevro Corp. (“Nevro”) announced that Boston Scientific Corp. and Boston Scientific Neuromodulation Corp. (collectively, “Boston Scientific”) have filed a patent infringement lawsuit alleging Nevro’s manufacture, use and sale of the Senza® system infringes certain of Boston Scientific’s patents covering technology related to stimulation leads, batteries and telemetry units. | d309964d8k.htm |
| 2016-11-29 | 8-K | 2016-11-28 | 8.01 Other Events | 8.01 On November 28, 2016, Nevro Corp. (“Nevro”) announced that it has filed a lawsuit for patent infringement against units of Boston Scientific. | d279747d8k.htm |
| 2016-11-22 | 8-K | 2016-11-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 16, 2016, the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Nevro Corp. (the “Company”) approved the annual base salaries (effective January 1, 2017) and target annual performance bonuses for 2017 and equity compensation awards for Andrew Galligan, the Company’s Chief Financial Officer, and Doug Alleavitch, the Company’s Vice President, Quality. | nvro-8k_20161116.htm |
| 2016-11-21 | 8-K | 2016-11-15 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement | 1.01 On November 15, 2016, Nevro Corp. (the “Company”) entered into a new multi-year supply agreement (the “CCC Agreement”) with Centro de Construccion de Cardioestimuladores del Uruguay S.A. (“CCC”), a subsidiary of Integer Holdings Corporation, pursuant to which CCC has agreed to a revised arrangement with regard to the manufacture and supply of the Company’s implantable pulse generators (“IPGs”). 1.02 Reference is made to the disclosures set forth in Item 1.01 above with regard to the termination of the March 2015 Agreement, which disclosures are incorporated by reference herein. | nvro-8k_20161121.htm |
| 2016-11-07 | 8-K | 2016-11-07 | 2.02 Results of Operations and Financial Condition | 2.02 On November 7, 2016, Nevro Corp. (“Nevro” or the “Company”) issued a press release relating to its financial results for the three and nine months ended September 30, 2016. | nvro-8k_20161107.htm |
| 2016-08-23 | 8-K/A | 2016-05-18 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 As reported in the Original Filing, at the annual meeting of the Company’s stockholders, the Company’s stockholders voted on three proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 6, 2016. | d424799d8ka.htm |
| 2016-08-08 | 8-K | 2016-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2016, Nevro Corp. (“Nevro” or the “Company”) issued a press release relating to its financial results for the three and six months ended June 30, 2016. | nvro-8k_20160808.htm |
| 2016-06-13 | 8-K | 2016-06-07 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 On June 7, 2016, Nevro Corp. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J. P. Morgan Securities LLC and Morgan Stanley & Co. LLC as representatives of the several underwriters named in Schedule 1 thereto (collectively, the “Underwriters”) to issue and sell $150.0 million aggregate principal amount of 1.75% Convertible Senior Notes due 2021 (the “Initial Notes”) in a public offering pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-211864) (the “Registration Statement”) and a related prospectus, including the related prospectus supplement, filed with the Securities and Exchange Commission (the “Offering”). 1.02 On June 13, 2016, the Company used approximately $21.0 million of the net proceeds from the issuance of the Notes to repay all amounts owed (including the associated closing and repayment fees) under its term loan agreement, dated as of October 24, 2014, by and among the Company, Capital Royalty Partners II L.P. (“Capital Royalty”) and certain affiliates of Capital Royalty party thereto as lenders (as amended, the “Credit Agreement”), and related documents. 2.03 The information set forth in Item 1.01 of this Current Report on Form 8-K under the heading “Supplemental Indentures Relating to Convertible Senior Notes” is incorporated by reference into this Item 2.03. 3.02 The Company entered into the Warrant Transactions with the Option Counterparties in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). | d211326d8k.htm |
| 2016-05-23 | 8-K | 2016-05-18 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On May 18, 2016, Nevro Corp. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). | d199195d8k.htm |
| 2016-05-09 | 8-K | 2016-05-09 | 2.02 Results of Operations and Financial Condition | 2.02 On May 9, 2016, Nevro Corp. (“Nevro” or the “Company”) issued a press release relating to its financial results for the three months ended March 31, 2016. | d178189d8k.htm |
| 2016-03-15 | 8-K | 2016-03-09 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 In connection with its executive leadership succession plan, on March 9, 2016, the Board of Directors (the “Board”) of Nevro Corp. (“Nevro” or the “Company”) approved a new compensatory arrangement for each of Michael DeMane and Rami Elghandour. | d157082d8k.htm |
| 2016-02-29 | 8-K | 2016-02-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 25, 2016, the Board of Directors (the “Board”) of Nevro Corp. (“Nevro” or the “Company”) approved an executive leadership succession plan pursuant to which Michael DeMane, the Company’s current Chief Executive Officer and a member of the Board, will transition into the role of Executive Chairman of the Board, and Rami Elghandour, the Company’s current President, would assume the role of President and Chief Executive Officer, in each case, effective as of June 1, 2016 (the “Transition Date”). | d150525d8k.htm |
| 2016-02-29 | 8-K | 2016-02-29 | 2.02 Results of Operations and Financial Condition | 2.02 On February 29, 2016, Nevro Corp. (“Nevro” or the “Company”) issued a press release relating to its financial results for the three months and full year ended December 31, 2015. | d150602d8k.htm |
| 2016-01-11 | 8-K | 2016-01-11 | 2.02 Results of Operations and Financial Condition | 2.02 On January 11, 2016, Nevro Corp. (the “Company”) issued a press release announcing preliminary unaudited revenue for the fourth quarter and year ended December 31, 2015. | d113702d8k.htm |